-M V Relling Researcher Activity Profile

Research Author Detailed Information 

M V Relling Publication Rate By Year

M V Relling has published 1 paper(s) in 2002, 1 paper(s) in 2006, 9 paper(s) in 2007, 1 paper(s) in 2008, for a total of 12 research publications in total.

M V Mv Relling Author Information

LAST NAME: relling

FIRST NAME: M V

INITIALS: mv

AFFILIATION:

Papers

M V Relling's Publication Record

1. Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Year Published: 2007
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, and College of Pharmacy, University of Tennessee, Memphis, TN, USA.
2. Pharmacogenomics: challenges and opportunities. Year Published: 2006
Vanderbilt University, Nashville, Tennessee, USA. dan.roden@vanderbilt.edu
3. The pharmacogenetics research network: from SNP discovery to clinical drug response. Year Published: 2007
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA. kathy.giacomini@ucsf.edu
4. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Year Published: 2007
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, University of Tennessee, Memphis, Tennessee, USA.
5. Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Year Published: 2007
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
6. Genome scan implicates adhesion biological pathways in secondary leukemia. Year Published: 2007
Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
7. Continue to study childhood ALL. Year Published: 2007
8. Continue to study childhood ALL. Year Published: 2007
9. Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Year Published: 2007
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
10. Acute lymphoblastic leukemia. Year Published: 2002
University Hospital, Medizinische Klinik III, Theodor Stern Kai 7, Frankfurt, Germany.
11. Continue to study childhood ALL. Year Published: 2007
12. Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy? Year Published: 2008
CDepartment of Oncology, St Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA. ching-hon.pui@stjude.org